Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Minami

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|July 9, 2026
Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 studyNoriyoshi Iriyama, Naoto Takahashi, Katsumichi Fujimaki, et al.
Annals of Hematology|February 8, 2025
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 studySatoshi Iyama, SungGi Chi, Masashi Idogawa, et al.
The Lancet. Haematology|December 22, 2015
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trialJun Imagawa, Hideo Tanaka, Masaya Okada, et al.
Cancer Science|May 17, 2022
Feasibility and clinical utility of comprehensive genomic profiling of hematological malignanciesSuguru Fukuhara, Yuji Oshikawa-Kumade, Yasunori Kogure, et al.
Blood|August 18, 2021
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIsDelphine Réa, Michael J Mauro, Carla Boquimpani, et al.
Cancer Science|February 16, 2023
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01Naoko Hosono, SungGi Chi, Takahiro Yamauchi, et al.
Leukemia|January 30, 2023
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBLAndreas Hochhaus, Delphine Réa, Carla Boquimpani, et al.
Blood Advances|May 7, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBLMichael J Mauro, Yosuke Minami, Andreas Hochhaus, et al.
Cancer Chemotherapy and Pharmacology|January 24, 2025
Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)Masaki Ri, Shinsuke Iida, Kosuke Saito, et al.
International Journal of Hematology|September 21, 2017
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 studyNaoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|July 9, 2026
Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 studyNoriyoshi Iriyama, Naoto Takahashi, Katsumichi Fujimaki, et al.
Annals of Hematology|February 8, 2025
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 studySatoshi Iyama, SungGi Chi, Masashi Idogawa, et al.
The Lancet. Haematology|December 22, 2015
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trialJun Imagawa, Hideo Tanaka, Masaya Okada, et al.
Cancer Science|May 17, 2022
Feasibility and clinical utility of comprehensive genomic profiling of hematological malignanciesSuguru Fukuhara, Yuji Oshikawa-Kumade, Yasunori Kogure, et al.
Blood|August 18, 2021
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIsDelphine Réa, Michael J Mauro, Carla Boquimpani, et al.
Cancer Science|February 16, 2023
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01Naoko Hosono, SungGi Chi, Takahiro Yamauchi, et al.
Leukemia|January 30, 2023
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBLAndreas Hochhaus, Delphine Réa, Carla Boquimpani, et al.
Blood Advances|May 7, 2025
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBLMichael J Mauro, Yosuke Minami, Andreas Hochhaus, et al.
Cancer Chemotherapy and Pharmacology|January 24, 2025
Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)Masaki Ri, Shinsuke Iida, Kosuke Saito, et al.
International Journal of Hematology|September 21, 2017
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 studyNaoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, et al.
Pageof 11